Literature DB >> 8314939

High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations.

J Fang1, J W Gorrod.   

Abstract

An isocratic high-performance liquid chromatographic (HPLC) system was developed to analyze haloperidol and its potential metabolites. These compounds included 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP), haloperidol N-oxide (HNO), reduced haloperidol (RHAL), the 1,2,3,6-tetrahydropyridine analogue and its N-oxide, and the pyridinium ion from haloperidol (HP+). The HPLC system comprised a Hypersil CPS5 column with a mobile phase of acetonitrile (67%) and ammonium acetate (final concentration 10 mM) which was adjusted to pH 5.4 by acetic acid. The solvent was delivered at 1 ml/min. RHAL and CPHP were determined by an ultraviolet detector at 220 nm with a detection limit of 1 nmol/ml. All other compounds were determined at 245 nm and had a detection limit of 0.3 nmol/ml. This system was used to analyze a microsomal metabolic mixture of haloperidol. It was found that all above compounds except HNO were metabolites of haloperidol. In addition, two other metabolites were also well separated in this HPLC system which are proposed to be oxygenated haloperidol and the pyridone analogue of haloperidol. The HPLC system was used to carry out quantitative metabolic studies of haloperidol. It was found that the metabolism of haloperidol exhibits large inter-species differences. The apparent enzyme kinetic parameters were also determined using mice microsomes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314939     DOI: 10.1016/0378-4347(93)80318-x

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Formation of pyridinium species of haloperidol in human liver and brain.

Authors:  D W Eyles; J J McGrath; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

2.  Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.

Authors:  J Fang; G B Baker; P H Silverstone; R T Coutts
Journal:  Cell Mol Neurobiol       Date:  1997-04       Impact factor: 5.046

Review 3.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

4.  Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis to overcome kanamycin resistance.

Authors:  Ankita Punetha; Keith D Green; Atefeh Garzan; Nishad Thamban Chandrika; Melisa J Willby; Allan H Pang; Caixia Hou; Selina Y L Holbrook; Kyle Krieger; James E Posey; Tanya Parish; Oleg V Tsodikov; Sylvie Garneau-Tsodikova
Journal:  RSC Med Chem       Date:  2021-10-05

5.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics.

Authors:  Johnique Billups; Cynthia Jones; Tanise L Jackson; Seth Y Ablordeppey; Shawn D Spencer
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

7.  Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.

Authors:  J Fang; D Zuo; P H Yu
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

8.  Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices.

Authors:  J Fang; P H Yu
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.